

,||
,¶
Surgery
Biostatistics
¶ Health Services, University of Washington, Seattle, Washington
|| Department of Surgery, Childrens Hospital and Regional Medical Center, Seattle, Washington
| ABSTRACT |
|---|
|
|
|---|
Methods. A systematic comprehensive review of the scientific literature was conducted with the PubMed (National Library of Medicine) database for the period from 1981 to 2004. This reproducible search identified all publications dealing with treatment of empyema in the pediatric population (<18 years of age). A meta-analysis was performed with studies with adequate data summaries for
1 of the outcomes of interest for both treatment groups.
Results. Sixty-seven studies were reviewed. Data were aggregated from reports of children initially treated nonoperatively (3418 cases from 54 studies) and of children treated with a primary operative approach (363 cases from 25 studies). The populations were similar in age. Patients who underwent primary operative therapy had a lower aggregate in-hospital mortality rate (0% vs 3.3%), reintervention rate (2.5% vs 23.5%), length of stay (10.8 vs 20.0 days), duration of tube thoracostomy (4.4 vs 10.6 days), and duration of antibiotic therapy (12.8 vs 21.3 days), compared with patients who underwent nonoperative therapy. In 8 studies for which meta-analysis was possible, patients who received primary operative therapy were found to have a pooled relative risk of failure of 0.09, compared with those who did not. Meta-analysis could not be performed for any of the other outcome measures investigated in this review. Similar complication rates were observed for the 2 groups (5% vs 5.6%).
Conclusions. These aggregate results suggest that primary operative therapy is associated with a lower in-hospital mortality rate, reintervention rate, length of stay, time with tube thoracostomy, and time of antibiotic therapy, compared with nonoperative treatment. The meta-analysis demonstrates a significantly reduced relative risk of failure among patients treated operatively.
Key Words: empyema treatment video-assisted thoracoscopic surgery thrombolytics thoracotomy
Abbreviations: VATS, video-assisted thoracoscopic surgery MeSH, Medical Subjects Heading
Empyema affects nearly 1 of every 150 children hospitalized with pneumonia,1 ranging in incidence from 0.4 to 6 cases per 1000 pediatric admissions.2 Although empyema is a common entity, its management remains controversial. Therapeutic options include antibiotics, thoracentesis,3 thoracostomy tube,4,5 fibrinolytics,6,7 video-assisted thoracoscopic surgery (VATS),8,9 and thoracotomy.10,11 Treatment measures are often used in a stepwise manner. The role of primary operative therapy has yet to be determined.
Empyema is a dynamic process that progresses through 3 stages.12 Stage 1, the early exudative phase, involves a collection of thin reactive fluid and few cells in the pleural space. Stage 2 is the fibropurulent phase, with large quantities of white cells and fibrin deposition, which results in the formation of loculations. Stage 3 is the organizing phase, in which a thick fibrinous peel encases the lung, limiting its mobility. Although drainage with tube thoracostomy (chest tube) and antibiotics may be adequate for stage 1 disease, the presence of loculations and fibrinous adhesions may limit the success of this therapy.
Empyema is most often treated with primary nonoperative therapy (defined as antibiotics and thoracentesis/chest tube drainage). This approach is associated with prolonged hospitalization and frequent failure, requiring salvage operative interventions. Many series have demonstrated that children who experience failure of nonoperative therapy exhibit improvement after thoracotomy or VATS,1315 especially if the procedure is performed early.16,17 On the basis of these results, many pediatric surgeons have come to consider primary operative therapy a more effective and efficient approach for treating children with empyema.8 However, there are limited data to guide this consideration. The purpose of this study was to review systematically the outcomes from published reports of cases of primary operative therapy and nonoperative therapy, to better assess the role of primary operative therapy in the treatment of children with empyema.
| METHODS |
|---|
|
|
|---|
Search Strategy
The search strategy was conducted using the following 6 search strategies; searches 1 to 4 were limited to all children, 0 to 18 years, English: (1) Medical Subjects Heading (MeSH) "empyema, pleural" with subheadings complications OR drug therapy OR mortality OR prevention and control OR surgery OR therapy; limited to clinical trial (publication type) OR (NOT MeSH "case reports" AND [publications types metanalysis OR practice guidelines OR review OR MeSH "epidemiologic methods"]); (2) MeSH "pleural effusion" with subheadings complications OR drug therapy OR mortality OR prevention and control OR surgery OR therapy; limited to clinical trial (publication type) OR (NOT MeSH "case reports" AND key word parapneumonic); (3) MeSH "empyema" (major heading, no explosion) AND MeSH "empyema" (MeSH, no explosion) with subheadings drug therapy OR surgery OR therapy AND key word pleural OR parapneu* AND (NOT MeSH "case reports"); (4) MeSH "empyema, pleural" (MeSH) OR ("empyema" [MeSH, no explosion] AND "pleural diseases" [MeSH]) AND ("thrombolytic therapy" OR "fibrinolytic agents" OR "fibrinolytic agents" [pharmacological action]); (5) key words fibrinolytic* AND empyema AND (child* OR infant* OR pediatric* OR pediatric* OR adolescen* OR teen*); (6) key words empyema* AND (child* OR infant* OR pediatric* OR pediatric* OR adolescen* OR teen*) limited to in process titles.
Inclusion Criteria/Exclusion Criteria
The search was limited to studies among children (018 years of age) published in the English language. Case reports, abstracts only, letters, reviews, and incomplete reports (studies that did not specify
1 outcomes of interest among children with empyema) were excluded. Studies that included only patients who experienced failure of nonoperative therapy were excluded from this analysis. Studies that included patients who were treated nonoperatively with salvage fibrinolytic therapy were included in this study. Data were also collected for patients treated with primary fibrinolytic therapy and were classified separately. In studies that described patients who underwent primary operative therapy, it was stated clearly that patients underwent the operative intervention before thoracentesis or tube thoracostomy. In studies that compared different primary therapeutic modalities, data were collected for groups of children who received either nonoperative or primary operative therapy only if the number of patients and
1 of the outcomes of interest were reported clearly for that treatment group.
Search Yield
Two hundred eighteen publications were detected. Case reports, abstracts, incomplete reports, studies with adults, and reviews were excluded (n = 151). Sixty-three articles were reviewed, and citations from those reports were used to identify additional studies (n = 26), of which 4 met the inclusion criteria for this review. A single investigator, using criteria that were established before study initiation, reviewed 67 studies, and experts in data aggregation, statistical analysis, and pediatric surgery reviewed the study data.
Definitions
Primary Nonoperative Therapy
Primary nonoperative therapy was defined as children being treated initially with antibiotics and thoracentesis and/or tube thoracostomy.
Primary Operative Therapy
Primary operative therapy was defined as children being treated initially with antibiotics and either VATS or thoracotomy.
Primary Fibrinolytic Therapy
Primary fibrinolytic therapy was defined as children being treated with fibrinolytics either at the time of or shortly after (<24 hours) tube thoracostomy. Fibrinolytics were defined as agents causing dissolution of fibrin through enzymatic activity and included most commonly urokinase and streptokinase.
Outcomes
Adverse outcomes included the in-hospital mortality rate, therapeutic failure rate, length of hospitalization, total days with tube thoracostomy, total days with antibiotic therapy, and complication rate. All of these outcomes had consistent definitions across all studies, with the exception of complication rate. Failure rate was defined as failure of a primary intervention necessitating subsequent operative intervention. Conversion of a primary VATS to a thoracotomy was not considered a failure but was accounted for in the results. For both nonoperative therapy and primary operative therapy, complications typically included pneumothorax, bronchopleural fistula, persistent or recurrent empyema, bleeding, and wound infection. In some series, ICU admissions were considered complications and were included in the complication rate. Other series reported ICU stays as routine care, and such stays were excluded as complications in those studies. Because there were few standard definitions of complications and most authors did not provide definitions of complications, overall aggregate complication rates, as described by the authors, were calculated.
Analyses
The proportions of patients who died, who underwent reoperation, and who experienced complications were calculated for children with empyema treated with nonoperative or primary operative therapy. The average age, total number of hospital days, total chest tube days, and total days with antibiotic therapy were also determined. In aggregations of data, the denominator for each evaluation was derived from the total number of cases in those studies that included the outcome being evaluated. A subset analysis of the results published in the past 5 years (19992004) was performed to evaluate the effects of advances in the treatment of empyema over time.
We conducted a formal meta-analysis of the differences between patients treated nonoperatively and those treated operatively. Of the 67 studies reviewed, 13 contained adequate data summaries for
1 of the outcomes of interest for both treatment groups (primary operative therapy and primary nonoperative therapy). Outcomes analyzed statistically included the mortality rate, failure rate, length of hospital stay, days with chest tube inserted, and duration of antibiotic therapy. For continuous outcomes (length of stay, days with chest tube inserted, and duration of antibiotic therapy), only studies that reported the number of subjects and the outcome mean and SD for all treatment groups were included. Studies that reported incomplete summaries and those that reported nonparametric summaries (median and interquartile range) were excluded from analysis. All of these 13 studies were published since 1999. Only 1 study8 stated that patients in the primary operative therapy group were separated in time from patients in the primary nonoperative therapy group.
All meta-analyses were performed with Stata software (Stata Corp, College Station, TX), as described by Egger et al.18 For binary outcomes, Mantel-Haenszel relative risk estimates were obtained for each study and were pooled across studies. For continuous outcomes, standardized mean differences were calculated within each study and pooled. For all meta-analyses, a
2 test of heterogeneity across studies was performed to test for significant inconsistencies in the findings. Beggs test for publication bias was also performed.19
| RESULTS |
|---|
|
|
|---|
|
Primary Operative Therapy
Outcome data for children with empyema treated with primary operative therapy (n = 363) were reported in 25 cases (Table 2). There were no reported perioperative deaths. A failure rate of 2.5% (range: 012.5%) and a complication rate of 5% (range: 015.3%) were reported, based on 304 cases (22 studies) and 258 cases (17 studies), respectively. The average age of the primarily operatively treated cohort was 5.5 ± 1.3 years, based on 287 cases (19 studies). The average length of stay was 10.8 ± 4.8 days, based on 293 cases (22 studies). The average length of time the thoracostomy tube remained in place was 4.4 ± 1.6 days, based on 161 cases (10 studies). Antibiotics were used for an average of 12.8 ± 3.8 days, based on 68 cases (5 studies). VATS was performed for 48.4% and thoracotomy was performed for 48.2% of patients with primary operative therapy. One study did not specify the mode of primary operative therapy and accounted for the remaining 3.4% of children with primary operative therapy.
|
|
A meta-analysis of outcomes for nonoperative and operative therapy was performed. Table 4 gives the number of articles that had usable data for each outcome. Mortality rates could not be evaluated in this way because no deaths were observed in either treatment group in any of these reports. Only failure rates were reported in a sufficient number of articles to allow for a formal meta-analysis. In all 8 studies included in this meta-analysis, patients who received primary operative therapy had a lower risk of failure, compared with those who did not (Fig 1). In the 3 largest of these studies, the relative risk of failure was significantly less than 1 (P < .05). Overall, the pooled relative risk of failure among these patients was highly significant at 0.09 (P < .0001). A
2 test did not show significant evidence of heterogeneity (P = .60) across studies, but Beggs test showed evidence of publication bias (P < .05). The meta-analysis was inconclusive for the remaining outcomes, because there were few articles and a large degree of heterogeneity across studies. There were no studies that compared VATS with thoracotomy.
|
|
| DISCUSSION |
|---|
|
|
|---|
11 times higher in the primary nonoperative therapy group, compared with the primary operative therapy group. Findings in this review indicate that primary operative therapy decreases the length of hospitalization and has a lower failure rate. However, >76% of patients who undergo primary nonoperative therapy experience resolution of the disease without operative intervention. Although this relatively high success rate favors a stepwise approach to management, a less invasive primary operative intervention has the potential to interrupt the progression of empyema, to eliminate the increased pain and discomfort associated with prolonged thoracostomy tube use, and to reduce hospital stays by avoiding salvage operative therapy. In centers that use general anesthesia for chest tube placement, the use of VATS may be more appropriate, given the comparable effectiveness of VATS with respect to nonoperative therapy and the similar utilization of resources. More evidence is needed to determine whether management of pediatric empyema with primary operative therapy leads to improved outcomes. The limitations of this retrospective evaluation demonstrate the importance of a prospective, randomized trial evaluating stage-specific disease to answer this question.
Similarly, fibrinolytics (streptokinase and urokinase) have become part of the armamentarium for treatment of pediatric empyema. In the past 50 years, the majority of experience with fibrinolytic therapy has been among adults. In most of the pediatric studies reviewed, fibrinolytic therapy was used for children who failed to exhibit improvement with nonoperative therapy alone. In fact, salvage fibrinolytic therapy may cause worsening of intrapleural loculations and increase the difficulty of the VATS procedure.37 Three studies in this review used fibrinolytics as a primary therapy, with a reduction in the failure rate but a higher reported complication rate, compared with primary nonoperative therapy.
Other issues may play a role in the selection of one therapeutic approach over another. Meier et al23 reported a retrospective cost analysis and found that the costs for patients treated with intensive nonoperative therapy (>2 chest tubes) were 3 times as great as those for patients whose empyema was treated adequately with
2 chest tubes. This suggested that simple empyema could be treated with nonoperative measures in a cost-effective manner. However, prolonged chest tube drainage correlated with progression of the empyema, resulting in subsequent surgery and added expense. When patients treated with primary VATS were compared with children treated nonoperatively or with salvage VATS, primary VATS appeared to be more cost-effective than salvage VATS or nonoperative treatment for patients who required >2 chest tubes.
This review has several limitations. For example, one important variable in therapeutic decision-making is the stage of disease. Unfortunately, many studies in this review did not detail stage-specific results. Although nonoperative therapy may be successful for the treatment of stage 1 disease, the characteristic loculations and pleural peel found in late-stage disease make adequate drainage of the infected pleural space and expansion of the lung through simple drainage more difficult. It is unclear whether the 23% treatment failure rate found for the group of patients treated with tube thoracostomy drainage and antibiotics represented data for a patient population with stage 2 or 3 disease. Conversely, although patients undergoing operative therapy can be presumed to have advanced disease, operative success might be linked to an earlier stage of disease, in the absence of stage-specific data. The lack of stage-specific data complicates statistical comparisons of outcomes across treatment groups. Furthermore, many of the studies were not randomized trials, and the meta-analysis was subject to all of the selection biases that might be present in those studies. Criteria for selection of therapy likely evolved with time; the care of empyema among children has progressed in the past 20 years, with the inclusion of fibrinolytics and VATS. This creates a potential limitation for comparisons of VATS with nonoperative treatment. For this reason, we performed an aggregate analysis of reported outcomes from studies published in the past 5 years, and we found little impact on the outcome variables during that time. In the meta-analysis, the significant reduction in the failure rate was driven by the 3 largest studies in the analysis.8,9,22 The benefit of operative therapy might be somewhat inflated in the study by Cohen et al,8 because all primary nonoperative cases were taken from 19891997, whereas all primary operative cases were taken from 20002001, which means that the findings might be confounded by time differences. The less-invasive nature of VATS, compared with thoracotomy, might have caused a reduction in the threshold to proceed to operative intervention for patients who experienced failure of nonoperative therapy, resulting in an artificially elevated failure rate. In institutions with limited resources, patients treated nonoperatively might have had a low failure rate, resulting in prolonged hospitalization. A publication bias would exist if results were reported after proficiency in the operative technique had been obtained, falsely improving outcomes. In the meta-analysis evaluating failure rates, Beggs test gave a significant result, suggesting the possibility of publication bias (if not providing conclusive evidence of it).
| CONCLUSIONS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Reprint requests to (J.R.A.) Department of Surgery, University of Washington, Box 356410, Seattle, WA 98105. E-mail: javansin{at}u.washington.edu
No conflict of interest declared.
| REFERENCES |
|---|
|
|
|---|
lu E, Tekant G, Erdogan E, et al. Evolving experience in the management of pleural empyema.
Eur J Pediatr Surg. 2004;14
:75
78[CrossRef][ISI][Medline]This article has been cited by other articles:
![]() |
S. S. Shah, C. M. DiCristina, L. M. Bell, T. Ten Have, and J. P. Metlay Primary Early Thoracoscopy and Reduction in Length of Hospital Stay and Additional Procedures Among Children With Complicated Pneumonia: Results of a Multicenter Retrospective Cohort Study Arch Pediatr Adolesc Med, July 1, 2008; 162(7): 675 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-T. T. Li and R. L. Gates Hold Those Scalpels--Reply Arch Pediatr Adolesc Med, July 1, 2008; 162(7): 698 - 699. [Full Text] [PDF] |
||||
![]() |
W. J. Durbin and C. Stille Pneumonia Pediatr. Rev., May 1, 2008; 29(5): 147 - 160. [Full Text] [PDF] |
||||
![]() |
E. Cohen, M. Weinstein, and D. N. Fisman Cost-effectiveness of Competing Strategies for the Treatment of Pediatric Empyema Pediatrics, May 1, 2008; 121(5): e1250 - e1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-T. T. Li and R. L. Gates Primary Operative Management for Pediatric Empyema: Decreases in Hospital Length of Stay and Charges in a National Sample Arch Pediatr Adolesc Med, January 1, 2008; 162(1): 44 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Padman, K. A. King, S. Iqbal, and P. J. Wolfson Parapneumonic Effusion and Empyema in Children: Retrospective Review of the duPont Experience Clinical Pediatrics, July 1, 2007; 46(6): 518 - 522. [Abstract] [PDF] |
||||
![]() |
B. A. Kurt, K. M. Winterhalter, R. H. Connors, B. W. Betz, and J. W. Winters Therapy of Parapneumonic Effusions in Children: Video-Assisted Thoracoscopic Surgery Versus Conventional Thoracostomy Drainage Pediatrics, September 1, 2006; 118(3): e547 - e553. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Mattei and J. L. Allen Treatment of Empyema in Children: From Hippocrates' Time to the Present, and Back Again Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 110 - 111. [Full Text] [PDF] |
||||
![]() |
R. Roseby Primary Operative Versus Nonoperative Therapy for Pediatric Empyema Pediatrics, April 1, 2006; 117(4): 1462 - 1463. [Full Text] [PDF] |
||||
![]() |
C.W. Bollen, M.O. Hoekstra, and H.G.M. Arets Pooling of Studies in Meta-analysis of Observational Research Leads to Precise but Spurious Results Pediatrics, January 1, 2006; 117(1): 261 - 262. [Full Text] [PDF] |
||||
![]() |
C. Cavett Pediatric Empyema: Operative versus Nonoperative Primary Therapy AAP Grand Rounds, October 1, 2005; 14(4): 40 - 40. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||